<DOC>
	<DOCNO>NCT00475956</DOCNO>
	<brief_summary>The purpose study determine maximum tolerated dos AZD2171 , combination AZD0530 , treat patient advance solid tumour safe , tolerable efficacious .</brief_summary>
	<brief_title>Safety Tolerability Study AZD2171 Combination With AZD0530 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Written consent Cancer diagnosis &amp; stage Patients standard therapy exist World Health Organization ( WHO ) performance status 02 One measurable lesion Prostate cancer Untreated unstable brain meningeal metastasis Specific laboratory range Pregnant breastfeed woman Any evidence severe uncontrolled disease Participation trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Advanced Solid Tumour</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Choriocarcinoma</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
</DOC>